History of Bretisilocin in Timeline
Bretisilocin, also known as GM-2505 or 5-fluoro-N-methyl-N-ethyltryptamine, is a serotonergic psychedelic tryptamine analogue under development as a treatment for major depressive disorder. It's a 5-fluorinated derivative of methylethyltryptamine (MET) and an analogue of dimethyltryptamine (DMT). The administration route for Bretisilocin is intravenous infusion.
2022: First Description in Literature
In 2022, Bretisilocin was first described in the scientific literature.
June 2025: Phase 2 Clinical Trials
In June 2025, Bretisilocin is in phase 2 clinical trials for the treatment of major depressive disorder, and a phase 2a trial has been completed, with the efficacy and safety data released.
August 2025: Acquisition by AbbVie
In August 2025, AbbVie acquired Bretisilocin from Gilgamesh Pharmaceuticals for up to $1.2 billion.
Trending
2 months ago Arsenal vs Sporting CP Champions League Quarterfinals: Arteta's Call and Broadcast Details
4 months ago Cardi B Addresses Tour Commitment, Phoenix Concert Details, and Expresses Gratitude.
1 year ago Carli Lloyd's emotional Hall of Fame speech: An apology to USWNT teammates.
1 month ago Knicks fans dominate 76ers series: Hart's jab, Maxey's admission, ticket donations.
3 months ago Fox Sports' tweet on Israel baseball triggers meme, Anti-Semitic backlash on X.
Mikel Oyarzabal is a Spanish professional footballer who plays as a left winger or forward He is the captain of...
Popular
Elon Musk is a businessman and public official primarily known...
Michael Joseph Jackson the King of Pop was a highly...
Cristiano Ronaldo widely considered one of the greatest footballers captains...
Ron Harper is a retired American professional basketball player who...
Jalen Brunson is an American professional basketball player currently playing...
Graham Cunningham Platner is an American oyster farmer and Marine...